<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198068</url>
  </required_header>
  <id_info>
    <org_study_id>22122</org_study_id>
    <secondary_id>R01AR049772</secondary_id>
    <nct_id>NCT00198068</nct_id>
  </id_info>
  <brief_title>Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)</brief_title>
  <acronym>PROMISSE</acronym>
  <official_title>Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major
      clinical centers. The purpose of the study is 1) to determine whether certain proteins
      (called complement split products) that can injure healthy organs can be used to predict poor
      pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid
      syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic
      factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thrombosis and pregnancy loss are common features of systemic lupus erythematosus (SLE),
      particularly in the presence of antiphospholipid (aPL) antibodies. The in vivo mechanisms by
      which aPL antibodies lead to vascular events and, specifically, to recurrent fetal loss are
      largely unknown. Studies in a mouse model of antiphospholipid antibody syndrome (APS)
      indicate that in vivo complement activation is necessary for fetal loss caused by aPL
      antibodies. This study represents an effort to translate these research observations on the
      potential role of complement activation in the pathogenesis of aPL antibody-mediated
      pregnancy loss to a clinically relevant human study.

      In addition, studies in humans and mice have shown 1) that the balance of circulating
      angiogenic and antiangiogenic factors predicts preeclampsia and fetal growth restriction in
      healthy women, 2) circulating antiangiogenic factors cause endothelial dysfunction and
      abnormal placental development in animal models, and 3) complement activation leads to
      elevated levels of circulating antiangiogenic factors and complement inhibition prevents
      increased levels of antiangiogenic factors, placental dysfunction and fetal growth
      restriction in a mouse model of APS. This study will permit testing the hypothesis that, like
      in healthy women, the balance of circulating angiogenic and antiangiogenic factors predict
      complications in women with SLE and APS and to translate the findings in animal models into
      humans.

      The PROMISSE Study is a prospective observational study that will follow 700 pregnant
      patients who will be grouped and analyzed according to the presence or absence of aPL
      antibodies and preexisting SLE. The patients are followed regularly during the course of the
      pregnancy, collecting medical and obstetrical information as well as serial blood specimens
      for complement and cytokine assays. The data obtained will be analyzed and used to identify
      mechanisms and predictors of poor fetal outcome. We expect that the insights provided through
      this study will suggest means to prevent, arrest or modify these conditions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Otherwise unexplained fetal death occurring after 12 weeks gestation</measure>
    <time_frame>End of pregnancy</time_frame>
    <description>Fetal death occurring after 12 weeks' gestation and not explained by chromosomal abnormalities, anatomic malformations, or congenital infections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal death prior to hospital discharge and due to complications of prematurity</measure>
    <time_frame>Time of neonatal death</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicated preterm delivery prior to 36 weeks' gestation because of gestational hypertension, preeclampsia-eclampsia or placental insufficiency</measure>
    <time_frame>End of pregnancy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Small for gestational age (SGA) &lt;5th %ile in the absence of anatomical or chromosomal abnormalities and/or delivery before 36 weeks because of intrauterine growth restriction (IUGR).</measure>
    <time_frame>End of pregnancy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age</measure>
    <time_frame>End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>End of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days neonate requires positive pressure ventilation</measure>
    <time_frame>Neonate discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of days neonate is hospitalized</measure>
    <time_frame>Neonate discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1: aPL+/SLE-</arm_group_label>
    <description>Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM &gt;= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM &gt;= 40 units; no SLE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: aPL+/SLE+</arm_group_label>
    <description>Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM &gt;= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM &gt;= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: aPL-/SLE+</arm_group_label>
    <description>No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: aPL-/SLE-</arm_group_label>
    <description>Healthy controls: no antiphospholipid antibodies; no SLE</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, whole blood, RNA, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients identified by investigators at each study site
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient pregnant with live intrauterine pregnancy, as defined by positive test for
             elevated β-HCG, but ≤ 12 weeks by gestation (for subjects without aPL antibodies) and
             ≤18 weeks (for subjects with aPL antibodies)

          -  Patient between the ages of 18-45 and able to give informed consent, or age &lt; 18 years
             with parental consent

          -  Hematocrit &gt; 26%

          -  For APL positive:

               -  aCL: IgG &gt;= 40 GPL units; IgM &gt;= 40 MPL units

               -  Positive LAC (RVVT, Kaolin, dilute TTI or PTT LA)

               -  Anti-β2GPI: IgG &gt;= 40 GPL units; IgM &gt;= 40 MPL units

          -  For control subjects:

               -  At least one successful pregnancy

               -  No history of fetal death (death of conceptus ≥ 10 weeks' gestation)

               -  No more than 1 miscarriage &lt; 10 weeks' gestation

               -  No history of positive aPL in local lab or positive aPL in core labs at screening

               -  Not currently a smoker

               -  No medical problems requiring chronic treatment

        Exclusion Criteria:

          -  Diabetes mellitus (Type I and Type II) antedating pregnancy

          -  Known or suspected hereditary complement deficiency (defined by CH50 = 0)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane E. Salmon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta M. Guerra, MS</last_name>
    <phone>212-774-7361</phone>
    <email>guerram@hss.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center/Hospital for Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta M Guerra, MS</last_name>
      <phone>212-774-7361</phone>
      <email>guerram@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Jill P. Buyon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta M Guerra, MS</last_name>
      <phone>212-774-7361</phone>
      <email>guerram@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Michael D. Lockshin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa R. Sammaritano, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyler R Cavin</last_name>
      <phone>801-585-7617</phone>
      <email>tyler.cavin@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ware Branch, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flint Porter, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Spitzer</last_name>
      <phone>416-506-9203</phone>
      <email>kspitzer@triofertility.com</email>
    </contact>
    <investigator>
      <last_name>Carl Laskin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hss.edu/clinical-trials.asp</url>
    <description>Clinical Trials at Hospital for Special Surgery</description>
  </link>
  <link>
    <url>http://www.hss.edu/conditions_promisse-largest-investigation-lupus-pregnancy-loss.asp</url>
    <description>The PROMISSE Study: The Nation's Largest Ever Investigation of Pregnancy Loss in Lupus</description>
  </link>
  <link>
    <url>http://www.disabled-world.com/health/autoimmunediseases/lupus/pregnancy-hope.php</url>
    <description>Pregnancy Safe for 80% of Women with Lupus</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467516/</url>
    <description>PROMISSE: progress in understanding pregnancy complications in patients with SLE</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/art.34402/abstract;jsessionid=B4F954E7332B1FE84FFC69A6082E9FF2.d04t03</url>
    <description>Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies</description>
  </link>
  <link>
    <url>http://www.hss.edu/newsroom_study-sheds-light-pregnancy-complications.asp</url>
    <description>Study Sheds Light on Pregnancy Complications and Overturns Common Belief</description>
  </link>
  <link>
    <url>http://www.lupus.org/research-news/entry/lupus-anticoagulant-affects-pregnancy-outcomes</url>
    <description>Lupus Anticoagulant Affects Pregnancy Outcomes</description>
  </link>
  <reference>
    <citation>Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004 Nov;10(11):1222-6. Epub 2004 Oct 17.</citation>
    <PMID>15489858</PMID>
  </reference>
  <reference>
    <citation>Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003 Dec;112(11):1644-54. Erratum in: J Clin Invest. 2004 Feb;113(4):646.</citation>
    <PMID>14660741</PMID>
  </reference>
  <reference>
    <citation>Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002 Jan 21;195(2):211-20.</citation>
    <PMID>11805148</PMID>
  </reference>
  <results_reference>
    <citation>Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter TF, Sammaritano L, Stephenson MD, Buyon J, Salmon JE. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012 Jul;64(7):2311-8. doi: 10.1002/art.34402.</citation>
    <PMID>22275304</PMID>
  </results_reference>
  <results_reference>
    <citation>Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Garabet L, Salmon JE. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015 Aug 4;163(3):153-63. doi: 10.7326/M14-2235.</citation>
    <PMID>26098843</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, Petri M, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29.</citation>
    <PMID>26432463</PMID>
  </results_reference>
  <results_reference>
    <citation>Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, Lockshin MD, Petri M, Merrill JT, Sammaritano LR, Kim MY, Salmon JE. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016 Jan 12;3(1):e000131. doi: 10.1136/lupus-2015-000131. eCollection 2016.</citation>
    <PMID>26835148</PMID>
  </results_reference>
  <results_reference>
    <citation>Yelnik CM, Porter TF, Branch DW, Laskin CA, Merrill JT, Guerra MM, Lockshin MD, Buyon JP, Petri M, Sammaritano LR, Stephenson MD, Kim MY, Salmon JE. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis Rheumatol. 2016 Aug;68(8):1964-9. doi: 10.1002/art.39668.</citation>
    <PMID>26990620</PMID>
  </results_reference>
  <results_reference>
    <citation>Buyon JP, Kim MY, Guerra MM, Lu S, Reeves E, Petri M, Laskin CA, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Salmon JE. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017 Jun 7;12(6):940-946. doi: 10.2215/CJN.11431116. Epub 2017 Apr 11.</citation>
    <PMID>28400421</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy outcomes</keyword>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>Antiphospholipid syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
    <mesh_term>Beta 2-Glycoprotein I</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Because the investigative team is still analyzing the data for biomarkers and genetics, the authors are not willing to make the data public at this time. Published study results can be found under Publications on the ClinicalTrials.gov site for this study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

